Condition

ALK Gene Mutation

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 15 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials15

Recruiting6

Common interventions25

Lead sponsors shown13

Clinical trials

15 shown

Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALKNCT05266846 · 2024-05-29

A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on LorlatinibNCT06378892 · 2024-03-15

Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB)NCT05724004 · 2023-10-05

Alectinib Pharmacokinetic in Patients With NSCLCNCT05713006 · 2022-05-01

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationNCT04322890 · 2020-04-16

Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI TherapyNCT03042221 · 2016-05-10

Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLCNCT07674524 · 2026-08-01

NOT_YET_RECRUITING

Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted TherapiesNCT05370469 · 2022-08-25

ACTIVE_NOT_RECRUITING

Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)NCT05200481 · 2022-05-18

ACTIVE_NOT_RECRUITING

A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLCNCT04849273 · 2021-07-28

Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)NCT06234579 · 2021-07-12

Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer PatientsNCT04708639 · 2019-06-19

Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid CancersNCT03868423 · 2019-03-20

Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475NCT03049618 · 2017-03-10

French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular TestingsNCT01700582 · 2012-04-01

Common interventions

Leading sponsors

Hunan Province Tumor Hospital 2 Intergroupe Francophone de Cancerologie Thoracique 2 Aarhus University Hospital 1 Centro di Riferimento Oncologico - Aviano 1 Fondazione Policlinico Universitario Agostino Gemelli IRCCS 1 Instituto Nacional de Cancerologia de Mexico 1 Karolinska University Hospital 1 Sameek Roychowdhury 1 Sun Yat-sen University 1 Turning Point Therapeutics, Inc. 1 University of Colorado, Denver 1 University of Southern California 1 University of Virginia 1

Trial status mix

RECRUITING6

ACTIVE_NOT_RECRUITING2

COMPLETED2

UNKNOWN2

NOT_YET_RECRUITING1

TERMINATED1

WITHDRAWN1

Phase mix

PHASE27

NA2

PHASE12

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.